NO20101069L - Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva - Google Patents

Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva

Info

Publication number
NO20101069L
NO20101069L NO20101069A NO20101069A NO20101069L NO 20101069 L NO20101069 L NO 20101069L NO 20101069 A NO20101069 A NO 20101069A NO 20101069 A NO20101069 A NO 20101069A NO 20101069 L NO20101069 L NO 20101069L
Authority
NO
Norway
Prior art keywords
antidepressants
hydrogen
affinity antagonists
certain nmda
fluorophenyl
Prior art date
Application number
NO20101069A
Other languages
English (en)
Inventor
Dennis Mccarthy
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20101069L publication Critical patent/NO20101069L/no
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Anvendelse av visse lavaffinitet-NMDA-antagonister som antidepressive midler. Foretrukne forbindelser inkluderer forbindelser av formel (I) R2 | R5 R1 ? CH2 ??? N | R4 R3 (I) Hvor R1 er pyridyl, fenyl eller 4-fluorfenyl; R2 er fenyl eller 4-fluorfenyl; R3 er hydrogen, C1-6 alkyl eller metoksykarbonyl; R4 er hydrogen eller metyl; og R5 er hydrogen eller COCH2NH2, og farmasøytisk akseptable salter derav.
NO20101069A 1999-03-23 2010-07-27 Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva NO20101069L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901077A SE9901077D0 (sv) 1999-03-23 1999-03-23 Novel use
PCT/SE2000/000540 WO2000056324A1 (en) 1999-03-23 2000-03-21 The use of certain affinity nmda antagonists as antidepressants

Publications (1)

Publication Number Publication Date
NO20101069L true NO20101069L (no) 2001-09-06

Family

ID=20414989

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20014345A NO330550B1 (no) 1999-03-23 2001-09-06 Anvendelse av NMDA-affinitetsantagonist som antidepressiva
NO20101069A NO20101069L (no) 1999-03-23 2010-07-27 Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20014345A NO330550B1 (no) 1999-03-23 2001-09-06 Anvendelse av NMDA-affinitetsantagonist som antidepressiva

Country Status (17)

Country Link
US (1) US6479553B1 (no)
EP (1) EP1162967A1 (no)
JP (1) JP4705717B2 (no)
KR (1) KR20010108368A (no)
CN (1) CN1160065C (no)
AR (1) AR029343A1 (no)
AU (1) AU774117B2 (no)
BR (1) BR0009225A (no)
CA (1) CA2359568A1 (no)
IL (1) IL145334A0 (no)
MX (1) MXPA01009448A (no)
MY (1) MY135916A (no)
NO (2) NO330550B1 (no)
NZ (1) NZ513148A (no)
SE (1) SE9901077D0 (no)
WO (1) WO2000056324A1 (no)
ZA (1) ZA200106859B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
MXPA05012493A (es) * 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
US8492106B2 (en) * 2004-05-24 2013-07-23 Universitat Zu Koln Identification methods for ergothioneine transporter modulators and therapeutic uses thereof
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
JP2008503475A (ja) * 2004-06-17 2008-02-07 フォーレスト ラボラトリーズ， インコーポレイテッド メマンチンの放出が改変された製剤
ES2483126T3 (es) 2004-06-17 2014-08-05 Merz Pharma Gmbh & Co. Kgaa Formulaciones de formas de dosificación de neramexano
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2588296A1 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
BRPI0923476A2 (pt) * 2008-12-24 2016-01-19 Astrazeneca Ab composto, métodos para tratar depressão em um ser humano, e grande distúrbio depressivo, e, composição farmacêutica
AU2010325960C1 (en) 2009-12-02 2015-08-06 Adamas Pharma, Llc Amantadine compositions and methods of use
JP2015501652A (ja) * 2011-12-14 2015-01-19 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇａｂｒ−ａ２診断
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
SI3066091T1 (sl) 2013-11-05 2019-09-30 Astrazeneca Ab NMDA antagonist predzdravila

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84305A (en) * 1987-02-06 1992-01-15 Fisons Corp 2-aminoacetamide derivatives
US5206248A (en) * 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
AU3897693A (en) * 1992-04-03 1993-11-08 Astra Aktiebolag Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders
EP0869122B1 (en) 1997-03-31 2002-12-04 Korea Research Institute Of Chemical Technology Quinolinic sulfide derivatives acting as NMDA receptor antagonists and process for preparation thereof

Also Published As

Publication number Publication date
EP1162967A1 (en) 2001-12-19
JP2002539256A (ja) 2002-11-19
AU774117B2 (en) 2004-06-17
KR20010108368A (ko) 2001-12-07
MXPA01009448A (es) 2002-08-06
NO20014345L (no) 2001-09-06
CA2359568A1 (en) 2000-09-28
AR029343A1 (es) 2003-06-25
ZA200106859B (en) 2002-11-20
AU4156100A (en) 2000-10-09
CN1160065C (zh) 2004-08-04
CN1344157A (zh) 2002-04-10
WO2000056324A1 (en) 2000-09-28
JP4705717B2 (ja) 2011-06-22
BR0009225A (pt) 2001-12-26
US6479553B1 (en) 2002-11-12
SE9901077D0 (sv) 1999-03-23
MY135916A (en) 2008-07-31
NO20014345D0 (no) 2001-09-06
IL145334A0 (en) 2002-06-30
NZ513148A (en) 2003-10-31
NO330550B1 (no) 2011-05-16

Similar Documents

Publication Publication Date Title
NO306237B1 (no) Anvendelse av xantinderivater som antidepressive midler
DK0794949T3 (da) Hidtil ukendte 3,5-dioxo-(2H,4H)-1,2,4-triazinderivater, fremstilling heraf og deres anvendelse som lægemidler
TW330202B (en) Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals
MXPA04006322A (es) Derivados de 6-fluorobiciclo[3.1.0]hexano.
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
FR2805810B1 (fr) Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
DK1539734T3 (da) Quinolylpropylpiperidinderivater og deres anvendelse som antimikrobielle midler
DK0759919T3 (da) Azolidindioner som antihyperglykæmiske midler
NO20015172L (no) 1-metyl-erytromycin-derivater
MY116280A (en) A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
DE69231445D1 (de) Triazole enthaltende antifungizide mittel
SE9703376D0 (sv) A new combination
AR029343A1 (es) USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN
DK132188D0 (da) Anvendelse af tetrahydrobenz(c,d)indol-6-carboxamider som anxiolytika
HRP20070529T3 (hr) Derivati imidazola kao antagonisti receptora glutamata
ES2191341T3 (es) Derivados de la 2-fenoxianilina.
ATE374750T1 (de) Serotoninwiederaufnahme-inhibitoren
CO5540322A2 (es) Nuevos derivados heterociclicos que comprenden un anillo de tetrahidroisoquinolina y uso farmaceutico de los mismos
NO20012965L (no) Sulfonyloksazolaminer som terapeutisk aktive forbindelser
EP1130015A4 (en) Pyridazinone derivatives
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII